The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Today’s Capital Access Note;
Given Avacta’s revised clinical testing strategy and the potential for sales to start in 2026/27, we estimate a risked current value for AVA6000 at this stage of testing of 106p/share rising to 217p/share on transition to Phase 2 with a total, current fully de-risked value of 996p per share.
This overlooked post by Timster at 15.02 is quite telling, the BoD has very carefully titled the RNS as ‘Shareholder Update …. ’. IMO this is a major hint, hiding in plain sight, that publishing the P1a story by other means to both selective and general audiences is imminent. I know we know that anyway, but in my view the title of the RNS is a confirmation of such.
I very much appreciate BB and X posts by people who have clearly invested a lot of time sleuthing and researching AVCT. Many posters have done a great deal over a long period to keep interest alive, spread the word and to educate through intelligent research.
Comments made about the low SP though, in my view, just don’t square up. It’s often mentioned how the market is thick as mince and that the SP is lower than when the trial started.
But the trial started when the market still believed in the LFT and if you take the LFT completely out of the equation, then the SP has risen an impressive seven hundred percent (ish) from about 20p in early 2020 to today’s price of around 140p.
The Mcap is currently a very respectable £400M-ish, treading water whilst traders and fudders try their luck and shares are slowly transferred from weak to strong hands. Patient holders should be well rewarded, there’s loads of news in the pipeline and I don’t think it’ll be long before the paradigm shift really kicks in.
A few things Al said:
Uptick in commercial interest.
No rush to raise capital, lots of options.
Will prioritise non dilutive sources of capital.
Shorter dev time, brings p2 study into 2024, simpler and at considerably lower cost with a cash runway that’s considerably longer.